Cargando…
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
Targeting the epigenome has been considered a compelling treatment modality for several cancers, including gliomas. Nearly 80% of the lower-grade gliomas and secondary glioblastomas harbor recurrent mutations in isocitrate dehydrogenase (IDH). Mutant IDH generates high levels of 2-hydroxyglutarate (...
Autores principales: | Park, Jong-Whi, Turcan, Şevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826741/ https://www.ncbi.nlm.nih.gov/pubmed/31652645 http://dx.doi.org/10.3390/cancers11101616 |
Ejemplares similares
-
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
por: Sun, Xueyuan, et al.
Publicado: (2021) -
Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas
por: Al-Ali, Ruslan, et al.
Publicado: (2019) -
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
por: Wang, Yuxiang, et al.
Publicado: (2020) -
Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015) -
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine
por: Turcan, Sevin, et al.
Publicado: (2013)